



Ansell Limited
A.B.N. 89 004 085 330
Level 3, 678 Victoria Street
Richmond, Victoria 3121, Australia
GPO Box 772 Melbourne
Victoria 3001, Australia
Telephone (+613) 9270 7270
Facsimile (+613) 9270 7300
www.ansell.com

17 October 2013

Company Announcements Office
Australian Securities Exchange Limited
Level 4, Exchange Centre
20 Bridge Street
SYDNEY NSW 2000

Dear Sir/Madam

Chairman's Address & CEO Presentation - 2013 AGM

The address to be given by the Chairman and the presentation to be made by the Chief Executive Officer at Ansell Limited's Annual General Meeting, to be held today, are attached.

Yours sincerely,

A handwritten signature in black ink, appearing to read "Craig M Cameron", with a long horizontal stroke extending to the right.

Craig M Cameron
Company Secretary



CHAIRMAN'S ADDRESS

2013 ANNUAL GENERAL MEETING

Ladies and Gentlemen,

When we last met, in October 2012, you were advised that while the global economic environment was proving a challenge the Ansell company outlook for the remainder of the 2013 financial year was positive and our global footprint and balanced portfolio of health and safety protection solutions was expected to be resilient in the difficult trading environment facing the Company.

It is pleasing to be able to report to you that after a first half where results were below expectations, your Company delivered a much improved second half performance and overall, the full year performance was pleasing. Ansell's diverse portfolio of health and safety protection solutions continues to be a major driver of the Company's ability to deliver consistent and sustained business performance.

The Company has clear and well defined strategies that are being pursued to accelerate sales and profit growth and deliver benefits and value creation to our stakeholders, under the leadership of our Chief Executive Officer, Magnus Nicolin.

Magnus will address you shortly and will speak specifically about the 2013 results of our global portfolio of businesses and the priorities and outlook for the current year.

In the 2013 year Company sales increased by 9 per cent over the prior year and Profit Attributable to shareholders was US\$139.2 million compared with the previous year of US\$133.0 million, an increase of 5 per cent. In the current global trading environment, this is a sound validation of Ansell's growth strategies. It is also pleasing to note that Ansell's operating cash flow position improved significantly in the second half of the year ending at US\$130.4 million, a 33 per cent increase on the prior year. Reported Earnings per Share of US106.5 cents was up 5 per cent on the previous year.

It was particularly pleasing that as a result of the Company's strong balance sheet and solid trading performance, the Board was able to continue with the history of steady dividend growth and declare an increased final dividend for the 2013 financial year of 22 AU cents per share. The total dividend for the 2013 financial year was therefore 38 AU cents per share, up 7 per cent on the previous year.

During the year Ansell completed four acquisitions, launched 48 new products and made significant investments in further product and process development, marketing, plant and equipment, logistics and its employees. The balance sheet is

strong and gives us the capacity to continue to pursue our growth strategies including our focus on the development of our position in emerging markets and to selectively invest in organic growth as well as attractive acquisition opportunities.

We ended the 2013 year with a stronger market presence and a new momentum in innovation and productivity that has been carried into the current year.

In January of this year, we opened of our new Industrial and Specialty Markets Research and Development Center in Colombo, Sri Lanka. This center, now fully functional, houses some of the world's most innovative work in the area of personal protective equipment. The center is co-located with one of Ansell's largest manufacturing sites, has laboratory space, technical testing equipment and a very flexible pilot manufacturing line allowing quick testing of prototypes thus contributing to shortening the time to market for new products.

Our business has been enhanced by the integration of the four new acquisitions this past year. These acquisitions involved the integration of thousands of products and employees into the Ansell family. Though highly complex, we have already benefited from the value of integrating these companies through: access to new markets, development of new verticals, springboards to new and exciting opportunities and not least the opportunity to welcome new employees and new leaders with diverse experiences and backgrounds to Ansell.

Our Company is committed to building an inclusive and accessible organisation through the development of a culture that embraces diversity. We recognise the value and advantages of having a diverse and inclusive workplace. Our talented and diversified workforce is a key competitive advantage and we are committed to seeking out and retaining the best people we are able to and thus ensure strong and sustained business growth and performance.

The Board recognises its role in protecting and building sustainable value for all stakeholders. To enhance this function a Risk Committee of the Board has been established in order to keep pace with risk profile developments driven by the increasing geographic spread, size and complexity of our businesses in a rapidly changing world.

Our customers, suppliers and shareholders expect that our people demonstrate the highest standards of ethical conduct in all their business dealings. The Board strongly supports these expectations and monitors the corporate culture and seeks, along with the senior management team, to model and reinforce this culture across the organisation.

The Company seeks to have a Board of Directors with the range of skills and experiences that will soundly contribute to the development and implementation of our business strategies, in addition to their broader governance role. Given the nature the Ansell business we seek to recruit directors who have had career exposure to complex and international businesses and have demonstrated success in their contribution to both strategy development and implementation in many countries, including the developing world.

We are pleased to welcome Annie Lo as an independent Non-executive Director. Annie stands for election today and will speak to you shortly. Annie's diversified background in finance, developing markets and business integration will further strengthen our Board and complement the existing skills and business experience of our Board.

Peter Day has taken on the role of chairing the Audit and Compliance Committee. This has enabled Dale Crandall, who has done an outstanding job in that role for the last seven years to take up membership of all the Board committees - and allow us to better leverage his considerable skills and years of experience with Ansell.

The complexity and geographic spread of the Ansell business continues to increase the workload of the Directors, with increases in travel requirements and the number of days committed to reviewing business development opportunities and to meetings. I would like to thank my fellow Directors for their hard and diligent work over the past year.

This year we announced our first annual Ansell Innovation Awards to employees and teams on the leading edge of process, marketing and manufacturing innovation. These annual awards recognize those employees around the world who are thinking differently about going to market and anticipating end-user needs. Their ideas have resulted in millions of dollars in earnings improvements for Ansell either through cost savings, productivity gains, new product development or manufacturing efficiencies.


We have a committed workforce of over 13,000 spread across more than 50 sites in 35 countries dedicated to the development, manufacture and marketing of our products all around the world. Our businesses would not be in the strong position they are in today were it not for our people. We thank them all for their high levels of engagement and input.

Looking forward, we are clearly operating in a continually challenging global environment. That said, we see opportunities to grow both by acquisition and organically. This will see the Company continue to increase its breadth and depth of penetration of markets and market segments - and a continued stream of new products in both core and adjacent categories.

This is an exciting time for our Company, as the building blocks of our growth strategies are formed and we look to leverage these into sustained growth and continued improvement in the value created for all stakeholders - be they customers, employees, suppliers, shareholders or the communities we operate in.

Ansell Limited Annual General Meeting

Magnus Nicolin
Chief Executive Officer and Managing Director
17 October 2013



HyFlex® GAMMEX® SKYN® ACTIVARMR®

Ansell

Disclaimer

The following presentation has been prepared by Ansell Limited for information purposes only. The presentation may contain forward looking statements or statements of opinion

No representation or warranty is made regarding the accuracy, completeness or reliability of the forward looking statements or opinion or the assumptions on which either are based. All such information is, by its nature, subject to significant uncertainties outside of the control of the company

To the maximum extent permitted by law, the company and its officers do not accept any liability for any loss arising from the use of the information contained in this presentation

The information included in this presentation is not investment or financial product advice. Before making any investment decision, you should seek appropriate financial advice, which may take into account your particular investment needs, objectives and financial circumstances. Past performance is no guarantee of future performance



HyFlex® GAMMEX® SKYN® ACTIVARMR®



F'13 – Results Summary

	Statutory Result in Australian Dollars		Results in Operating Currency – US Dollars	
	F'12 A\$M	F'13 A\$M	F'12 US\$M	F'13 US\$M
Sales	1,218.3	1,340.0	1,255.3	1,372.8
Earnings Before Interest & Taxes (EBIT)	149.4	167.2	153.2	170.5
Profit Attributable (PA)	130.0	136.8	133.0	139.2
Earnings Per Share (EPS)	99.1¢	104.6¢	101.4¢	106.5¢
Dividend	35.5¢	38.0¢		

Note: US Dollars used unless otherwise specified. The USD information is non IFRS financial information provided to assist readers by reporting Ansell's results in the currency in which the business is managed. As in Ansell's past market releases, the USD information contained in this presentation is a direct conversion of the IFRS AUD financial information included in Ansell's statutory accounts, converted at the monthly average rate for profit and loss items and the year end rate for balance sheet items



HyFlex® GAMMEX® SKYN® ACTIVARMR®



F'13 – A Tough Year but We Gained Momentum and Finished Strongly

	F'12	F'13	Change	
Sales (\$M)	1,255	1,373	+ 9%	✓
EBIT (\$M)	153	171	+ 11%	✓
PA (\$M)	133	139	+ 5%	✓
EPS (¢)	1.01	1.07	+ 5%	✓
Free Cash (\$M)	97	128	+ 32%	✓



HyFlex® GAMMEX® SKYN® ACTIVARMR®



F'13 – External Environment a Headwind Throughout F13

- Foreign Exchange Impact
- Net Raw Material Costs
- Manufacturing costs (Labour, utilities, water)
- Global economy (weighted average)
- Competitive pressure up
- Government financial health (healthcare and defence spend)



HyFlex® GAMMEX® SKYN® ACTIVARMR®



F'13 – Strong Revenue and Profit Growth Delivered Through Successful Delivery Against Strategic Objectives

- Successful M&A transactions
- Significant NPD launches and early wins
- Solid portfolio optimization with GPADE up 120 BPS
- Improving manufacturing productivity and capability
- Continued Emerging Markets expansion
- Fighting spirit of our employees in a tough year



HyFlex® GAMMEX® SKYN® ACTIVARMR®


Ansell

F'13 – Successful M&A Transactions, Delivering In Line With Expectations Even In Challenging External Environment

- Four transactions completed including the largest deal since 1995
- Cost and cash-flow synergies better than plan
- These transactions collectively contribute to EBIT in line with the business cases
- Significant increase in capability and global strength emanate from these transactions



F'13 – Strong New Product Launches



HyFlex® GAMMEX® SKYN® ACTIVARMR®



F'13 - New Product Development

Industrial GBU

HyFlex® 11-840 Gloves

High performance Nitrile with extreme durability and Superior Fit for precision handling in abrasive applications



SM GBU

Oil, Gas & Mining

ActvArmr® Cold Weather, FR, Impact Glove

First to market flame resistant impact protective glove with insulation and waterproof barrier



Medical GBU

Gammex® Nitrile Anti Bacterial Glove

A world first glove designed to reduce cross contamination of micro organisms between surfaces and patients to reduce hospital acquired Infections



Sexual Wellness GBU

SKYN® Intense Feel

The world's first textured polyisoprene condom



HyFlex® GAMMEX® SKYN® ACTIVARMR®

Ansell

F'13 – Continued Emerging Markets Expansion

Growth YOY 17% (8% excluding acquisitions)

Other EMEA

- Growth YOY + 8%
- 5% of global sales (CIS, Turkey, Poland, CEE)

Latin America & Caribbean

- Growth YOY + 22%
- 8% of global sales (Mostly Brazil & Mexico)

Russia

- Growth YOY + 14%
- 4% of global sales

China

- Growth YOY + 14%
- 4% of global sales

India

- Growth YOY + 14%
- 2% of global sales

SE Asia

- Growth YOY + 17%
- 3% of global sales

Middle East & Africa

- Growth YOY + 34%
- 2% of global sales

Emerging Markets now represent 27% of Ansell's Sales
(25% in F'12)




HyFlex® GAMMEX® SKYN® ACTIVARMR®



F'13 – Capital Expenditure – Investment in the Future

US\$m





- ERP Oracle investment** being fine tuned. SAP being launched across EMEA. Major investment phase over.
- Acquisitions** have added 4 plants, SAP platform, significant new capacity
- Growth/expansion** investments have focused on adding new dipping lines, knitting machines, R&D technologies/pilot lines and platforms
- Profit Improvements** focus on reducing energy/utilities costs, providing for automation and increased throughputs – all driving higher GPADE
- Maintenance** investments increases in line with sales after a spike in F11 to catch up on overdue repairs



HyFlex® GAMMEX® SKYN® ACTIVARMR®



F'13 – Strong EPS/Dividend Growth and Share Price Appreciation Continued in F13



HyFlex® GAMMEX® SKYN® ACTIVARMR®



F'13 – All GBU's Achieved EBIT Growth With Margins Significantly Improved In The 2nd Half

\$M		F'12	F'13	
Industrial	- Sales	504.1	563.6	12%
	- Segment EBIT	83.7	92.0	10%
	- EBIT/Sales	16.6%	16.3%	
Specialty Markets	- Sales	177.5	230.0	30%
	- Segment EBIT	7.2	11.7	63%
	- EBIT/Sales	4.1%	5.1%	
Medical	- Sales	356.4	349.5	-2%
	- Segment EBIT	39.5	41.1	4%
	- EBIT/Sales	11.1%	11.8%	
Sexual Wellness	- Sales	217.3	229.7	6%
	- Segment EBIT	33.2	34.2	3%
	- EBIT/Sales	15.3%	14.9%	



HyFlex®

GAMMEX®


SKYN®

ACTIVARMR®

Ansell

We Made Progress On All Key Sustainability Measures

**Water Use
Reduction**



Energy Down



**Raw Material
Reductions**



**Productivity
Improvements**



HyFlex® GAMMEX® SKYN® ACTIVARMR®



F'13 – Ansell Value Drivers

Market Leadership

- Ansell is No 1 or 2 globally in everything it wants to compete in

Innovation Leadership

- Ansell is a leader in its field of innovation and has launched a stream of new products in the last two years

Strong Brands

- Ansell has a number of globally recognised brands that are leaders in their categories, such as Hyflex®, Gammex®, SKYN® and ACTIVARMR®

Increasingly efficient Manufacturing

- Ansell's plants are located in Malaysia, Thailand, Sri Lanka, India, Mexico, Brazil, Portugal, Lithuania and the US, with both Six Sigma and Lean efficiency programs

Guardian® Selling Solution

- Ansell's unique Guardian® selling solution actively used in Industrial and Specialty Markets and being developed for Medical

M&A Value Addition

- Ansell's global presence, efficient manufacturing, strong working capital management and balance sheet being used to extract synergistic value from acquisitions

THIS MAKES ANSELL AN INDUSTRY LEADER



HyFlex® GAMMEX® SKYN® ACTIVARMR®



F'13 - The Globalisation of Ansell continues

- Growth strategy defined in 2010 was designed to globalize products, capabilities, systems and staff – this has been very successful
- Acquisitions in Europe, North America and Latin America have contributed to global growth while we have continued to build on our strong market positions in Australia
- A significant majority of our institutional owners are now based outside Australia
- Ansell's main operating currency since 2003 is the US\$
- For these reasons Ansell will, from the start of the new fiscal year commencing July 1 2013, change its reporting currency from A\$ to US\$ only
- Ansell will also declare future dividends in US\$ and pay in US\$ or a small range of other currencies including the A\$ as requested by shareholders



HyFlex® GAMMEX® SKYN® ACTIVARMR®



F'13 – F'14 Guidance

As noted in August, the Company continues to see mixed economic conditions globally with significant political and economic uncertainty continuing to limit the pace of improvement.

Ansell is achieving moderate organic sales growth, but at a lower rate than anticipated for the first quarter. Building momentum in NPD sales and a strong new business pipeline, supports our expectation of strengthening sales trends through the year, with a similar 1H/2H pacing to that seen in F'13 also anticipated in F'14.

F'14 guidance remains as follows:

- EBIT growth of high single digits to low teens
- EPS in the range of US1.12¢ to US1.18¢ (up 5% - 11%).
 - Including a positive impact of Net Deferred Tax Asset/Non Operational Tax (DTA's/NOTI's) adjustments of US3¢ - US5¢, lower than the benefit seen in prior years

The Company is on track to close the acquisition of Midas during the quarter. Although it is expected to be neutral to EPS in F'14, it is expected the acquisition will be accretive going forward and the Company continues to view M&A as presenting opportunities for additional shareholder value creation.



HyFlex®

GAMMEX®

SKYN®

ACTIVARMR®



ANSELL PROTECTS



HyFlex[®] GAMMEX[®] SKYN[®] ACTIVARM[®]

